PDCD1 and melanoma: While we did not investigate whether altered metabolic dysregulation can be predictive of anti-PD-1 immunotherapy response, there is evidence that metabolic signaling pathways can serve as candidate biomarkers for ICI therapy efficacy, notably from a study linking increased oxidative metabolism in tumors to decreased likelihood of response to anti-PD-1 immunotherapy in melanoma patients (77).